March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Quantification of Vision Loss in Stargardt disease using Visual Field Modeling and Analysis
Author Affiliations & Notes
  • Richard G. Weleber
    Department of Ophthalmology, Oregon Health & Science University,
    Casey Eye Institute, Oregon Retinal Degeneration Center, Portland, Oregon
  • Elvira N. Chegarnov
    Department of Ophthalmology, Oregon Health & Science University,
    Casey Eye Institute, Oregon Retinal Degeneration Center, Portland, Oregon
  • Dawn Peters
    Department of Public Health and Preventative Medicine, Division of Biostatistics, OHSU,
    Casey Eye Institute, Oregon Retinal Degeneration Center, Portland, Oregon
  • Footnotes
    Commercial Relationships  Richard G. Weleber, and OHSU have a patent application for Visual Field Modeling and Analysis (P); Elvira N. Chegarnov, None; Dawn Peters, None
  • Footnotes
    Support  Hear See Hope Foundation; The Grousbeck Family Foundation; Foundation Fighting Blindness; and Research to Prevent Blindness.

Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4107. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Richard G. Weleber, Elvira N. Chegarnov, Dawn Peters; Quantification of Vision Loss in Stargardt disease using Visual Field Modeling and Analysis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4107.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

The vision loss in Stargardt (STGD) disease begins with a small, regular scotoma that, with time, becomes larger, irregular, and paracentric from eccentric viewing. Eventually, the peripheral field is affected. We present data on measures of field loss and on test-retest variability.

 
Methods:
 

32 eyes of 8 males and 8 females, average age 47.2 yrs (SD=16.0, range: 20.8, 66.8) with at least one mutant allele of ABCA4 were studied. IRB approval and informed consent were obtained. Static perimetry was performed on separate days, using the Octopus 900 perimeter (Haag-Streit, Köniz, Switzerland), stimulus size V, the GATE strategy, and a centrally condensed grid of 184 points extending from 56° nasally to 80° temporally. Using Visual Field Modeling and Analysis (VFMA) software, sensitivity data were fit with a thin-plate spline to create 3-dimensional models of the Hill of Vision (Figure), from which the sensitivity volume (dB-sr) for the total field (HOV), Total Volume Loss (TVL), and scotoma volume (SV) were independently measured for test and retest sessions.

 
Results:
 

The Table presents the intraclass correlation coefficients (ICC) and confidence intervals for HOV, TVL, and SV1 and SV2 as rated by the two graders. To avoid artificial inflation of the ICC, extreme observations were removed. Test-retest and grader agreements were strong for HOV and TVL, but variable for SV. Test-retest and grader agreements tended to be high for smaller scotomas but less so for large scotomas that approached the edge of the grid and when fixation was eccentric and unstable.

 
Conclusions:
 

VFMA enables quantification of the magnitude and extent of vision loss that can serve as endpoints for clinical trials. Improved fixation control during testing should reduce test-retest variability.  

 

 
Keywords: imaging/image analysis: clinical • visual fields • retinal degenerations: hereditary 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×